Remicade (infliximab) is now the first biologic approved for ulcerative colitis

May 2006

Remicade (infliximab) is now the first biologic approved for ulcerative colitis in Canada.

It's for moderate to severe ulcerative colitis in patients who haven't responded to conventional therapy...5-ASA, steroids, etc.

Remicade can induce remission...prevent colectomy...and reduce or eliminate steroid use.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

how to treat depression that just doesn't seem to go away
Women's Health Evista to prevent breast cancer
Women's Health whether VAGINAL estrogens are safe for women taking aromatase inhibitors
Women's Health OTC antiFUNGALS at the first sign of a problem even though most vaginal infections are actually BACTERIAL
confusion between Wellbutrin SR, Novo-Bupropion SR, and the new Wellbutrin XL
ADHD drug monographs will now include statements about the potential risk for sudden cardiac death
Obesity & Weight Loss the new diabetes drug, Byetta (exenatide), for weight loss
Ophthalmology Soft contact lens users are hearing warnings about serious fungal eye infections
Infectious Diseases Truvada (tenofovir/emtricitabine) BEFORE risky behaviour to prevent HIV infection
Cardiology Patients are asking if they should stop taking the combination of Plavix (clopidogrel) plus aspirin
Cardiology how to prevent or delay hypertension
Cardiology if chocolate is healthy
Gastroenterology Remicade (infliximab) is now the first biologic approved for ulcerative colitis
Gastroenterology levofloxacin-based regimens for treatment-resistant H. pylori infections
Medication Errors medication reconciliation
Supplements Health Canada has now approved sales of SAMe (S-adenosyl-L-methionine)
Practice Email and postal addresses are changing for some Regional Adverse Reaction Centres